Pancreatic Cancer and the Family Connection: The Role of Advanced Practitioners in Screening and Educating Genetically At-Risk Individuals

Tracy Lowe,(1) PhD, MS, RN, Jane DeLuca,(1) PhD, MS, RN, CPNP-PC, Ludovico Abenavoli,(2) MD, PhD, MSc, and Luigi Boccuto,(1) MD

Pancreatic cancer is the third leading cause of cancer deaths in the United States. It has a 95% mortality rate within 5 years of the initial diagnosis. Pancreatic ductal adenocarcinoma is the most commonly diagnosed histotype. The avera...

Solid Pseudopapillary Neoplasm: A Single Institutional Case Series of a Rare Pancreatic Tumor

Kristen Oase,(1) MS, PA-C, Cheryl Meguid,(1) DNP, ACNP, Atsushi Oba,(1,2) Mohammed H. Al-Musawi,(1) MD, MSc, FIBMS-CTV, FRCS (Glasg), Alison Sheridan,(1) MD, Evan Norris,(1) MD, Sanjana Mehrotra,(1) MD, Mark A. Lovell,(3) MD, Richard D. Schulick,(1) MD, MBA, FACS, Steven A. Ahrendt,(1) MD, and Marco Del Chiaro,(1) MD, PhD, FACS

Purpose: Solid pseudopapillary neoplasms (SPN) are rare pancreatic cystic neoplasms with low malignant potential that tend to occur in young women. Due to the rarity of this disease, there are few large case series in the literature, and...

Multidisciplinary Management of Pancreatic Cancer

Pelin Cinar, MD, MS, and Patricia Zendejas, MSN, ANP-C, AOCNP®

At JADPRO Live Virtual 2021, presenters reviewed the epidemiology of pancreatic cancer, treatment options for patients with different stages of pancreatic cancer, and the most common symptoms and complications related to pancreatic cance...

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma

Doreen Grzelak, NP-C, AOCN®, AGN-BC

Pancreatic cancer is the fourth leading cause of death from cancer in both men and women. Pancreatic cancer is typically diagnosed at an advanced stage and has an overall 5-year survival of approximately 9.3%. The National Comprehensive ...

Pancreatic Ductal Adenocarcinoma: Characteristics of Tumor Microenvironment and Barriers to Treatment

Sujata Kane,(1) PA-C, Anne Engelhart,(1) ANP-BC, Jessica Guadagno,(1) PA-C, Aaron Jones,(1) ANP-BC, Innis Usoro,(2) and Edith Brutcher,(1) ANP-BC, AOCNP®

Pancreatic ductal adenocarcinoma remains a highly aggressive disease, with a 5-year relative survival rate of 10%. Numerous barriers to treatment exist, such as dense desmoplasia, infiltration of immune suppressor cells, inhibitory cytok...

Management of Acute Pancreatitis Associated With Checkpoint Inhibitors

Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Terri Cuddahy, RN, MSN, OCN®, and Carolyn Zawislak, MPAS, PA-C

Pancreatitis is a rare immune-related adverse event (irAE) associated with the use of immune checkpoint inhibitors (ICIs). It is more often associated with combined immunotherapy than by any single agent. Early signs of pancreatitis may ...

What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer

Multidisciplinary clinics for pancreatic cancer such as one established at Johns Hopkins offer advantages in the care of patients with pancreatic cancer. Advanced practitioners can play a role in multidisciplinary care, providing symptom...

Pancreatic Cancer

Pancreatic cancer remains one of the most feared cancer diagnoses due to the poor prognosis associated with the majority of cases. Most patients present with distant metastases, and 5-year relative survival rates have changed very little...

Patients With Pancreatic Cancer Need New Treatment Approaches

Collaborative Approach to Managing a 59-Year-Old Woman With Stage IIB Pancreatic Cancer and Diabetes

The American Diabetes Association and the American Cancer Society recently published a consensus statement on diabetes and cancer based on the increased risk of selected cancers, including malignancies of the liver, pancreas, endometrium...